Cheng Liu

Cheng Liu

Company: Eureka Therapeutics

Job title: Founder & CEO

Seminars:

Panel Discussion: Exploring the Potential of Soluble TCR Therapies to Redirect and Activate T Cells 1:30 pm

How do we enhance receptor-target interactions to develop safe and efficacious soluble TCR products? Beyond survival benefit, how do we define the clinical response rate to determine success in phase 3 clinical trials? What are the lessons that we have taken from antibodies?Read more

day: Day Two

Towards Safer, More Effective and Persistent T-Cell Therapies Against Solid Tumors: Targeting Intracellular Tumor Antigens with TCR-Mimic Antibody Redirected Antibody TCR (AbTCR) T-cell Therapy 12:00 pm

Targeting intracellular, tumor specific antigens by a TCR-mimic antibody (TCRm) with high affinity and specificity ARTEMIS® Antibody TCR (AbTCR) platform represents a novel CAR-TCR hybrid with optimal signaling strength of CAR and TCR Safety and efficacy validation of TCRm redirected T cells going after Alpha-fetoprotein (AFP) in advanced hepatocellular carcinomaRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.